Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
R&D Systems™ Recombinant Human IL-18/IL-1F4 Protein
Extensive quality control produces industry leading bioactivity and lot-to-lot consistency that instills confidence in results and ensures reproducibility. Applications: Bioactivity
Supplier: R&D Systems™ 9124IL050
This item is not returnable.
View return policy
Description
The Recombinant Human IL-18/IL-1F4 Protein is derived from E. coli. The Recombinant Human IL-18/IL-1F4 Protein has been validated for the following applications: Bioactivity.Specifications
Q14116 | |
3606 | |
50μg | |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70° C as supplied. 1 month, 2 to 8° C under sterile conditions after reconstitution. 3 months, -20 to -70° C under sterile conditions after reconstitution. | |
Iboctadekin, IFN-gamma-inducing factor, IGIF, IGIFIL-1 gamma, IL18, IL-18MGC12320, IL-1F4, IL1F4iboctadekin, IL-1g, Interferon gamma-inducing factor, interleukin 18 (interferon-gamma-inducing factor), Interleukin-1 gamma, interleukin-18 | |
IL18 | |
Unconjugated | |
Recombinant | |
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie™ Blue Staining |
Bioactivity | |
Predicted MW: 18kDa Observed MW: 18kDa, reducing conditions | |
E. coli-derived human IL-18/IL-1F4 protein Tyr37-Asp193 | |
<0.10 EU per 1μg of the protein by the LAL method. | |
IL-18/IL-1F4 | |
Measured by its ability to induce IFN-gamma secretion by KG-1 human acute myelogenous leukemia cells in the presence of TNF-alpha . The ED50 for this effect is typically 1.5-9ng/mL. | |
Human | |
E. coli-derived Tyr37-Asp193 |
Provide Content Correction
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?
Provide Content Correction